Key result
Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2 in the infarcted heart in situ, while the myocardial effects of celecoxib resembled those of NCX-4016.
Why the study?
How do celecoxib and NCX-4016 compare to aspirin in affecting PGI2, TXA2, and iNOS production in the infarcted heart in situ?
How do celecoxib and NCX-4016 compare to aspirin in affecting PGI2, TXA2, and iNOS production in the infarcted heart in situ?
In an infarcted heart in situ model, aspirin remains more effective than celecoxib or NCX-4016 at reducing myocardial PGI2 and TXA2 synthesis.
Answers are grounded in this paper and cite their sources.
Should not guide NSAID selection after MI; leaves open comparative cardiac effects of NO-releasing agents in human ischemia.
Several attempts have been made to replace aspirin with compounds without gastric toxicity; a cyclooxygenase-2 (COX-2) inhibitor, celecoxib, and a nitric oxide-aspirin, NCX-4016, have been developed for this purpose. This paper compares effects of celecoxib, NCX-4016 and aspirin on production of prostacyclin (PGI2) and thromboxane A2 (TXA2) and activation of the inducible form of nitric oxide synthase (iNOS) in infarcted heart in situ. Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2. Myocardial effects of celecoxib resemble those of NCX-4016, although the two compounds have different modes of action.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2001) studied Infarcted heart. Celecoxib and NCX-4016 vs. Aspirin was evaluated on Production of prostacyclin (PGI2) and thromboxane A2 (TXA2) and activation of inducible nitric oxide synthase (iNOS). Aspirin was most effective in reducing myocardial PGI2 synthesis and formation of TXA2 in the infarcted heart in situ, while the myocardial effects of celecoxib resembled those of NCX-4016.
Synapse has enriched 10 related papers. Consider them for comparative context: